Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2021 > Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

Denovo Biopharma LLC Announces Partner Aytu BioPharma Receives FDA Clearance and Orphan Drug Designation for Enzastaurin in Vascular Ehlers-Danlos Syndrome

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.